Case Name: In re CYCLOBENZAPRINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULE PATENT LITIGATION. Eurand, Inc. (now known as Aptalis Pharmatech, Inc.) and Anesta AG, Plaintiffs-Appellants, v. Anchen Pharmaceuticals, Inc. and Anchen, Inc., DefendantsAppellees
Court: United States Court of Appeals for the Federal Circuit
Jurisdiction: United States
Decision Date: 2011-08-31
Citations: 427 F. App'x 901
Docket Number: Nos. 2011-1408, 2011-1410, 2011-1411, 2011-1412
Parties: In re CYCLOBENZAPRINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULE PATENT LITIGATION. Eurand, Inc. (now known as Aptalis Pharmatech, Inc.) and Anesta AG, Plaintiffs-Appellants, v. Anchen Pharmaceuticals, Inc. and Anchen, Inc., DefendantsAppellees.
Judges: 
Reporter: West's Federal Appendix
Volume: 427
Pages: 901–901

Head Matter:
In re CYCLOBENZAPRINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULE PATENT LITIGATION. Eurand, Inc. (now known as Aptalis Pharmatech, Inc.) and Anesta AG, Plaintiffs-Appellants, v. Anchen Pharmaceuticals, Inc. and Anchen, Inc., DefendantsAppellees.
Nos. 2011-1408, 2011-1410, 2011-1411, 2011-1412.
United States Court of Appeals, Federal Circuit.
Aug. 31, 2011.

Opinion:
ON MOTION
ORDER
Upon consideration of the appellants' motion to withdraw these appeals, and the motion to revise the official caption,
It Is Ordered That:
(1) The motion to withdraw the appeals is granted. The appeals are dismissed.
(2) The motion to revise the caption is granted. The revised official caption is reflected above.
(3) Each side shall bear its own costs.
(4) Any other pending motions are denied as moot.